Suppliers and packagers for generic pharmaceutical drug: PENICILLIN G SODIUM

PENICILLIN G SODIUM

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sandoz	PENICILLIN G SODIUM	penicillin g sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	065068	ANDA	Sandoz Inc	0781-6153-95	10 VIAL in 1 CARTON (0781-6153-95) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL (0781-6153-94)	2001-02-26

Who Supplies Penicillin G Sodium?

Last updated: April 26, 2026

Penicillin G sodium supply chains are dominated by large, regulated generic and fermentation-oriented manufacturers, with additional volume from API and intermediate suppliers that ship completed sterile sodium salts and/or fermentation-derived penicillin acids for formulation. Market access is typically governed by (1) whether the supplier provides the drug substance (penicillin G acid or sodium salt), (2) whether they ship directly to sterile injectables or to repackagers/formulators, and (3) whether their product is registered in the target country’s drug listings.

What are the main supplier categories for penicillin G sodium?

1. Drug-substance manufacturers (API/penicillin core)

   • Produce penicillin G acid (or penicillin G potassium/sodium salts) from fermentation and chemical conversion.
   • Ship to formulation plants making sterile injectables.

2. Finished-dose manufacturers (sterile injectables)

   • Produce and fill/finish sterile powder for injection or vials containing penicillin G sodium.
   • Often supply wholesalers and hospital distribution networks under local marketing authorizations.

3. Repackagers and parallel distributors

   • Source from finished-dose manufacturers and resell in target markets under their own distribution or labeling arrangements.

4. Contract manufacturing organizations (CMOs)

   • Support sterile filling, packaging, and quality testing for finished products, usually under the brand/marketing authorization holder.

Which manufacturers supply penicillin G sodium (global)?

Below are widely reported major producers of penicillin-class antibiotics and penicillin derivatives, including suppliers that commercially provide penicillin G sodium products or penicillin G active material used to make penicillin G sodium injectables.

Major global manufacturer groups (penicillin-class presence)

Company	What it typically supplies	Competitive relevance for penicillin G sodium
Pfizer	Penicillin-class antibiotics and sterile injectables (historically and via markets with legacy products)	Deep regulatory footprint and established sterile manufacturing network
Teva	Generic injectables and antibiotics portfolios (market-by-market)	High-volume distribution and tender participation in multiple regions
Sandoz (Novartis)	Generic antibiotics, sterile injectables (market-by-market)	Global quality systems and procurement scale
Mylan/Viatris	Generic injectables and antibiotics (market-by-market)	Tender-ready supply in EU/NA channels
Aurobindo Pharma	API and finished generics in antibiotics categories (market-by-market)	Strong API capability feeding sterile and non-sterile products
Hikma	Generic injectables including older antibiotics (market-by-market)	Sterile capability and global commercial reach
Baxter (legacy/market presence)	Injectable antibiotics in some jurisdictions historically	Institutional supply relationships
Local/regional sterile makers	Finished penicillin G sodium vials for local markets	Often the direct tender supplier for hospital systems

Note: Penicillin G sodium is marketed under different strengths, package formats, and national labels, so the “who supplies” answer is materially market-specific. The companies above are consistently represented across penicillin-family production and generic antibiotic commercialization globally.

Which API/intermediate suppliers are most relevant?

Penicillin G sodium supply usually traces back to fermentation-derived penicillin intermediates and conversion steps. Common API-relevant supplier capabilities include:

• Fermentation and penicillin isolation
• Penicillin G acid generation
• Salt formation (sodium conversion)
• Downstream purification and crystallization
• Sterile manufacturing handoff (for finished products) or non-sterile API shipment (for formulation)

In practice, procurement teams source in one of two ways:

• API procurement: buy penicillin G acid or penicillin G sodium API and formulate under the local regulatory pathway.
• Finished-dose procurement: buy sterile penicillin G sodium vials/powder for injection directly.

What documentation and supplier qualification typically gate penicillin G sodium supply?

Penicillin G sodium is an older, widely used antibiotic, but procurement still requires strict quality and regulatory documentation:

Standard qualification artifacts (procurement-ready)

• GMP certificate covering manufacture of penicillin G active substance and/or sterile finished product
• DMF/ASMF (where applicable) for the API manufacturing site
• CoA and batch release documentation
• Stability data (shelf-life and in-use period aligned to label)
• Sterility assurance and endotoxin results for finished sterile vials
• Container closure integrity evidence for powder-for-injection presentations
• Allergen and beta-lactam handling controls (containment, validated cleaning, cross-contamination prevention)

Which product forms dominate the market?

Penicillin G sodium is primarily supplied as sterile powder for injection or vial presentations intended for IV/IM use, typically in strengths such as:

• 1,000,000 units (IU) per vial
• 5,000,000 units (IU) per vial

Exact strengths vary by region and manufacturer labeling. Procurement decisions should match the hospital formulary unitization (IU) and reconstitution volumes specified on local labels.

How do buyers typically source penicillin G sodium?

Procurement tends to follow three routes:

1. Direct finished-dose tenders

   • Hospitals and distributors buy vials under locally approved marketing authorizations.
   • Best for supply assurance and shortest regulatory handling.

2. API-to-formulation

   • Formulators or repackagers buy drug substance and manufacture sterile product locally.
   • Best for price leverage and supply continuity where finished-dose approvals lag.

3. Distributor-managed alternates

   • Distributors switch among multiple authorized SKUs when a supplier experiences batch constraints.
   • Critical for maintaining continuity during fermentation-cycle or sterile-line maintenance windows.

What are the biggest supply risks that affect penicillin G sodium availability?

The supply chain is sensitive to constraints common to fermentation-based antibiotics and sterile manufacture:

• Fermentation capacity and media/feedstock availability
• Downstream purification line availability
• Regulatory or inspection events at API or sterile manufacturing sites
• Sterile filling bottlenecks (vial line uptime, lyophilization capacity if used, packaging constraints)
• Batch-specific yield and impurity profiles driving release outcomes

How to map supplier coverage to “who can actually deliver”

Procurement teams generally score suppliers on deliverability rather than brand recognition:

• Is the supplier authorized in the target country’s drug registry for penicillin G sodium?
• Can the supplier ship sterile vials vs API only?
• Do they support the required vial strength and packaging configuration?
• Do they consistently provide CoA documentation aligned to tender requirements?
• Do they have backup sites or established second-source arrangements?

Supplier short-list approach (actionable for R&D, QA, and procurement)

A workable short list for penicillin G sodium should include:

• Two finished-dose suppliers covering your tender SKU (strength, vial size, packaging)
• One API supplier to serve as a contingency for formulation or repackaging continuity
• One local sterile fill/finish partner if you are a formulator or repackager operating under a validated sterile process

Key Takeaways

• Penicillin G sodium supply is split between API/penicillin intermediate manufacturers and finished-dose sterile injectable producers, with procurement decisions driven by whether you need sterile vials or drug substance.
• Global supplier presence tends to concentrate among major generic and sterile-capable manufacturers with established antibiotic portfolios, backed by fermentation-derived API supply networks.
• Deliverability depends on local regulatory authorization, strength-specific packaging, and batch release and sterility QA documentation.
• The primary operational risks are tied to fermentation yield/capacity, API purification, and sterile filling line constraints.

FAQs

1) Can I source penicillin G sodium as API instead of finished sterile vials?

Yes. Penicillin G sodium supply is available as drug substance in many procurement models, with formulation and sterile manufacture handled separately by the buyer’s approved process.

2) What unit conventions should I expect when procuring penicillin G sodium?

Many markets label by International Units (IU) per vial, with common presentations including 1,000,000 IU and 5,000,000 IU strengths, depending on local authorization.

3) What quality documents matter most for procurement of penicillin G sodium?

GMP certification for the manufacturing site, CoA, batch release records, stability data aligned to label life, and sterility/endotoxin results for sterile finished products are standard gating items.

4) Which stage is most likely to constrain supply during shortages?

Supply bottlenecks most often occur at fermentation and downstream purification (for API/penicillin core) or at sterile filling/packaging (for finished injectables).

5) Is supplier qualification harder for penicillin-class antibiotics than for other generics?

Qualification remains stringent for all antibiotics, but beta-lactam handling controls, validated cleaning to prevent cross-contamination, and sterility assurance requirements tend to be especially scrutinized for penicillin-class sterile injectables.

References

[1] FDA. (n.d.). Drug shortages. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-shortages
[2] EMA. (n.d.). Public assessment reports and product information. European Medicines Agency. https://www.ema.europa.eu
[3] WHO. (2016). WHO good manufacturing practices for pharmaceutical products: Main principles. World Health Organization. https://www.who.int/publications
[4] FDA. (n.d.). cGMP regulations. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents